Farreny A, Aguado J, Ochoa S, Haro JM, Usall J. The role of negative symptoms in the context of cognitive remediation for schizophrenia. Schizophr Res. 2013 Oct;150(1):58-63.
Farreny A, Aguado J, Ochoa S, Huerta-Ramos E, Marsà F, López-Carrilero R, Carral V, Haro JM, Usall J. REPYFLEC cognitive remediation group training in schizophrenia: looking for an integrative approach. Schizophr Res. 2012 Dec;142(1-3):137-44. doi: 10.1016/j.schres.2012.08.035.
Fleming A, Olson JA, Sharp PF, Goatman KA, Philip S. Response to 'Improved automated screening of diabetic retinopathy' by Carlos M. Oliveira et al. Ophthalmologica. 2012 Jan 1;227(3):173. doi: 10.1159/000334922
Graham CN, Mauskopf J, Lawson AH, Ascher-Svanum H, Bruhn D, Watson PR. Validating an industry-sponsored model comparing the cost-effectiveness of atypical antipsychotics in the treatment of schizophrenia. Schizophr Res. 2010 Apr 1;117(2-3):398-9.
Juniper M, Le TK, Mladsi D. The epidemiology, economic burden, and pharmacological treatment of chronic low back pain in France, Germany, Italy, Spain and the UK: a literature-based review. Expert Opin Pharmacother. 2009 Nov 1;10(16):2581-92. doi: 10.1517/14656560903304063.
Weiner JR, Toy EL, Sacco P, Duh MS. Costs, quality of life, and treatment compliance associated with antibiotic therapies in patients with cystic fibrosis: a review of the literature expert. Expert Opin Pharmacother. 2008 Apr;9(5):751-66.
Lillienberg L, Zock JP, Kromhout H, Plana E, Jarvis D, Toren K. A population-based study on welding exposures at work and respiratory symptoms. Ann Occup Hyg. 2008 Mar;52(2):107-15.
Cropper ML, Haile M, Lampietti J, Poulos C, Whittington D. The demand for a malaria vaccine: evidence from Ethiopia. J Dev Econ. 2004 Oct 1;75(1):303-18.